Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
Neural Regen Res ; 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38845223

ABSTRACT

ABSTRACT: Spinal cord injuries have profound detrimental effects on individuals, regardless of whether they are caused by trauma or non-traumatic events. The compromised regeneration of the spinal cord is primarily attributed to damaged neurons, inhibitory molecules, dysfunctional immune response, and glial scarring. Unfortunately, currently, there are no effective treatments available that can fully repair the spinal cord and improve functional outcomes. Nevertheless, numerous pre-clinical approaches have been studied for spinal cord injury recovery, including using biomaterials, cells, drugs, or technological-based strategies. Combinatorial treatments, which target various aspects of spinal cord injury pathophysiology, have been extensively tested in the last decade. These approaches aim to synergistically enhance repair processes by addressing various obstacles faced during spinal cord regeneration. Thus, this review intends to provide scientists and clinicians with an overview of pre-clinical combinatorial approaches that have been developed toward the solution of spinal cord regeneration as well as update the current knowledge about spinal cord injury pathophysiology with an emphasis on the current clinical management.

2.
Neurobiol Dis ; 195: 106500, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38614275

ABSTRACT

Spinal Cord Injury (SCI) disrupts critical autonomic pathways responsible for the regulation of the immune function. Consequently, individuals with SCI often exhibit a spectrum of immune dysfunctions ranging from the development of damaging pro-inflammatory responses to severe immunosuppression. Thus, it is imperative to gain a more comprehensive understanding of the extent and mechanisms through which SCI-induced autonomic dysfunction influences the immune response. In this review, we provide an overview of the anatomical organization and physiology of the autonomic nervous system (ANS), elucidating how SCI impacts its function, with a particular focus on lymphoid organs and immune activity. We highlight recent advances in understanding how intraspinal plasticity that follows SCI may contribute to aberrant autonomic activity in lymphoid organs. Additionally, we discuss how sympathetic mediators released by these neuron terminals affect immune cell function. Finally, we discuss emerging innovative technologies and potential clinical interventions targeting the ANS as a strategy to restore the normal regulation of the immune response in individuals with SCI.


Subject(s)
Autonomic Pathways , Spinal Cord Injuries , Spinal Cord Injuries/immunology , Spinal Cord Injuries/physiopathology , Humans , Animals , Autonomic Pathways/immunology , Autonomic Nervous System/physiopathology , Autonomic Nervous System/immunology
3.
Front Immunol ; 15: 1354479, 2024.
Article in English | MEDLINE | ID: mdl-38444856

ABSTRACT

Introduction: The inflammatory response after spinal cord injury (SCI) is an important contributor to secondary damage. Infiltrating macrophages can acquire a spectrum of activation states, however, the microenvironment at the SCI site favors macrophage polarization into a pro-inflammatory phenotype, which is one of the reasons why macrophage transplantation has failed. Methods: In this study, we investigated the therapeutic potential of the macrophage secretome for SCI recovery. We investigated the effect of the secretome in vitro using peripheral and CNS-derived neurons and human neural stem cells. Moreover, we perform a pre-clinical trial using a SCI compression mice model and analyzed the recovery of motor, sensory and autonomic functions. Instead of transplanting the cells, we injected the paracrine factors and extracellular vesicles that they secrete, avoiding the loss of the phenotype of the transplanted cells due to local environmental cues. Results: We demonstrated that different macrophage phenotypes have a distinct effect on neuronal growth and survival, namely, the alternative activation with IL-10 and TGF-ß1 (M(IL-10+TGF-ß1)) promotes significant axonal regeneration. We also observed that systemic injection of soluble factors and extracellular vesicles derived from M(IL-10+TGF-ß1) macrophages promotes significant functional recovery after compressive SCI and leads to higher survival of spinal cord neurons. Additionally, the M(IL-10+TGF-ß1) secretome supported the recovery of bladder function and decreased microglial activation, astrogliosis and fibrotic scar in the spinal cord. Proteomic analysis of the M(IL-10+TGF-ß1)-derived secretome identified clusters of proteins involved in axon extension, dendritic spine maintenance, cell polarity establishment, and regulation of astrocytic activation. Discussion: Overall, our results demonstrated that macrophages-derived soluble factors and extracellular vesicles might be a promising therapy for SCI with possible clinical applications.


Subject(s)
Interleukin-10 , Spinal Cord Injuries , Humans , Animals , Mice , Transforming Growth Factor beta1 , Proteomics , Secretome , Spinal Cord Injuries/therapy
4.
Acta Neurol Belg ; 124(2): 603-610, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38441808

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) and has been known as T-cell mediated. However, the contribution of multiple cell types, notably natural killer (NK) cells, has also been reported. AIM: To quantify circulating total NK cells and its subpopulations, CD56 dim and bright, and to characterize the functional phenotype and IFN-γ and TNF-α production in relapsing-remitting patients treated with IFN-ß and in apparently healthy controls. RESULTS: CD56bright NK cells were found to be the least represented subpopulation. In relapse patients, the frequencies of IFN-γ-producing NK cells and their subpopulations were significantly decreased. In remission patients, CD56dim NK cells expressed high levels of HLA-DR and CD54. CONCLUSION: These results suggest that remission RRMS patients, although in an inactive stage of MS, present circulating NK cells with an activation phenotype, supporting the idea that NK cells may be relevant mediators in the MS pathophysiology.


Subject(s)
Multiple Sclerosis, Relapsing-Remitting , Multiple Sclerosis , Humans , Multiple Sclerosis, Relapsing-Remitting/metabolism , Multiple Sclerosis/metabolism , Killer Cells, Natural/metabolism , Central Nervous System , Gene Expression
5.
Int J Mol Sci ; 24(9)2023 Apr 22.
Article in English | MEDLINE | ID: mdl-37175391

ABSTRACT

The regional heterogeneity of microglia was first described a century ago by Pio del Rio Hortega. Currently, new information on microglia heterogeneity throughout central nervous system (CNS) regions is being revealed by high-throughput techniques. It remains unclear whether these spatial specificities translate into different microglial behaviors in vitro. We cultured microglia isolated from the cortex and spinal cord and analyzed the effect of the CNS spatial source on behavior in vitro by applying the same experimental protocol and culture conditions. We analyzed the microglial cell numbers, function, and morphology and found a distinctive in vitro phenotype. We found that microglia were present in higher numbers in the spinal-cord-derived glial cultures, presenting different expressions of inflammatory genes and a lower phagocytosis rate under basal conditions or after activation with LPS and IFN-γ. Morphologically, the cortical microglial cells were more complex and presented longer ramifications, which were also observed in vivo in CX3CR1+/GFP transgenic reporter mice. Collectively, our data demonstrated that microglial behavior in vitro is defined according to specific spatial characteristics acquired by the tissue. Thus, our study highlights the importance of microglia as a source of CNS for in vitro studies.


Subject(s)
Central Nervous System , Microglia , Animals , Mice , Microglia/metabolism , Neuroglia , Spinal Cord , Phagocytosis/physiology , Mice, Transgenic
6.
Animals (Basel) ; 13(8)2023 Apr 15.
Article in English | MEDLINE | ID: mdl-37106925

ABSTRACT

Chickens can acquire bacteria at different stages, and bacterial diversity can occur due to production practices, diet, and environment. The changes in consumer trends have led to increased animal production, and chicken meat is one of the most consumed meats. To ensure high levels of production, antimicrobials have been used in livestock for therapeutic purposes, disease prevention, and growth promotion, contributing to the development of antimicrobial resistance across the resident microbiota. Enterococcus spp. and Escherichia coli are normal inhabitants of the gastrointestinal microbiota of chickens that can develop strains capable of causing a wide range of diseases, i.e., opportunistic pathogens. Enterococcus spp. isolated from broilers have shown resistance to at least seven classes of antibiotics, while E. coli have shown resistance to at least four. Furthermore, some clonal lineages, such as ST16, ST194, and ST195 in Enterococcus spp. and ST117 in E. coli, have been identified in humans and animals. These data suggest that consuming contaminated animal-source food, direct contact with animals, or environmental exposure can lead to the transmission of antimicrobial-resistant bacteria. Therefore, this review focused on Enterococcus spp. and E. coli from the broiler industry to better understand how antibiotic-resistant strains have emerged, which antibiotic-resistant genes are most common, what clonal lineages are shared between broilers and humans, and their impact through a One Health perspective.

7.
Microorganisms ; 11(1)2023 Jan 03.
Article in English | MEDLINE | ID: mdl-36677414

ABSTRACT

Animal production is associated with the frequent use of antimicrobial agents for growth promotion and for the prevention, treatment, and control of animal diseases, thus maintaining animal health and productivity. Staphylococcus aureus, in particular methicillin-resistant S. aureus (MRSA), can cause a variety of infections from superficial skin and soft tissue infections to life-threatening septicaemia. S. aureus represents a serious public health problem in hospital and community settings, as well as an economic and animal welfare problem. Livestock-associated MRSA (LA-MRSA) was first described associated with the sequence (ST) 398 that was grouped within the clonal complex (CC) 398. Initially, LA-MRSA strains were restricted to CC398, but over the years it has become clear that its diversity is much greater and that it is constantly changing, a trend increasingly associated with multidrug resistance. Therefore, in this review, we aimed to describe the main clonal lineages associated with different production animals, such as swine, cattle, rabbits, and poultry, as well as verify the multidrug resistance associated with each animal species and clonal lineage. Overall, S. aureus ST398 still remains the most common clone among livestock and was reported in rabbits, goats, cattle, pigs, and birds, often together with spa-type t011. Nevertheless, a wide diversity of clonal lineages was reported worldwide in livestock.

8.
Clin Immunol ; 247: 109244, 2023 02.
Article in English | MEDLINE | ID: mdl-36706826

ABSTRACT

In arterial hypertension, increased Th17 cells and reduced Tregs are the hallmarks of immunological dysfunction and the basis for the investigation of immunomodulatory drugs. Although cholecalciferol is not a primary immunomodulator, it has recognized action on immune cells, leading us to hypothesise if cholecalciferol can induce a more tolerogenic phenotype in obese hypertensives. In a phase-2, single-centre, randomised, open, 24-week trial, we assigned adults with obesity-associated hypertension and vitamin D deficiency to receive usual therapy plus 50,000 IU/week of cholecalciferol or usual therapy alone. The primary endpoint was the percentual variation in T CD4+, T CD8+, Tregs, and Th17 cells. Secondary endpoints included the percentual variation in Th1, Tc1, Tc17, and monocytes and variation in the number of perivascular and non-perivascular macrophages, T CD4+ and T CD8+ lymphocytes in subcutaneous abdominal adipose tissue. A control group of 12 overweight normotensives was also evaluated for peripheral immune cells. A total of 36 obese hypertensives were randomised, 18 in each group. In comparison with normotensive controls, hypertensives presented higher percentages of T lymphocytes (p = 0.016), Tregs (p = 0.014), and non-classical monocytes (p < 0.001). At week 24, Th17 cells increased in control group (p = 0.017) but remained stable in cholecalciferol group. For Tregs, downregulation towards the values of normotensive controls was observed (p = 0.003), and in multivariate analysis, an increased loading in the setting of the cells of adaptive immunity observed (eigenvalue 1.78, p < 0.001). No changes were documented for monocytes. In adipose tissue, a baseline negative correlation between vitamin D and perivascular macrophages was observed (r = -0.387, p = 0.024) that persisted in the control group (r = -0.528, p = 0.024) but not in the cholecalciferol group, which presented an increase in non-perivascular macrophages (p = 0.029) at week 24. No serious adverse events were reported for all the participants. In this trial, we found that supplementation with cholecalciferol interfered with peripheral and adipose tissue immune cell profile, downregulating peripheral Th17 cells, but increasing the number of infiltrating subcutaneous adipose tissue macrophages. (Funded by Núcleo Estudos Hipertensão da Beira Interior; EudraCT number: 2015-003910-26).


Subject(s)
Cholecalciferol , Hypertension , Humans , Cholecalciferol/pharmacology , Cholecalciferol/therapeutic use , Th17 Cells , Obesity , Hypertension/drug therapy , Adipose Tissue , T-Lymphocytes, Regulatory
9.
Int J Mol Sci ; 23(22)2022 Nov 10.
Article in English | MEDLINE | ID: mdl-36430308

ABSTRACT

Spinal cord injury (SCI) is a disabling condition that disrupts motor, sensory, and autonomic functions. Despite extensive research in the last decades, SCI continues to be a global health priority affecting thousands of individuals every year. The lack of effective therapeutic strategies for patients with SCI reflects its complex pathophysiology that leads to the point of no return in its function repair and regeneration capacity. Recently, however, several studies started to uncover the intricate network of mechanisms involved in SCI leading to the development of new therapeutic approaches. In this work, we present a detailed description of the physiology and anatomy of the spinal cord and the pathophysiology of SCI. Additionally, we provide an overview of different molecular strategies that demonstrate promising potential in the modulation of the secondary injury events that promote neuroprotection or neuroregeneration. We also briefly discuss other emerging therapies, including cell-based therapies, biomaterials, and epidural electric stimulation. A successful therapy might target different pathologic events to control the progression of secondary damage of SCI and promote regeneration leading to functional recovery.


Subject(s)
Spinal Cord Injuries , Humans , Nerve Regeneration/physiology , Recovery of Function/physiology , Neuroprotection
10.
Pathogens ; 11(10)2022 Sep 27.
Article in English | MEDLINE | ID: mdl-36297167

ABSTRACT

Over the years, molecular typing of methicillin-resistant S. aureus (MRSA) has allowed for the identification of endemic MRSA strains and pathogenic strains. After reaching a peak of predominance in a given geographic region, MRSA strains are usually replaced by a new strain. This process is called clonal replacement and is observed worldwide. The worldwide spread of hospital-associated MRSA (HA-MRSA), community-associated MRSA (CA-MRSA) and livestock-associated MRSA (LA-MRSA) clones over the last few decades has allowed this microorganism to be currently considered a pandemic. In Portugal, most HA-MRSA infections are associated with EMRSA-15 (S22-IV), New York/Japan (ST5-II) and Iberian (ST247-I) clones. Regarding the strains found in the community, many of them are frequently associated with the hospital environment, namely the Pediatric, Brazilian and Iberian clones. On the other hand, a strain that is typically found in animals, MRSA clonal complex (CC) 398, has been described in humans as colonizing and causing infections. The ST398 clone is found across all animal species, particularly in farm animals where the economic impact of LA-MRSA infections can have disastrous consequences for industries. In contrast, the EMRSA-15 clone seems to be more related to companion animals. The objective of this review is to better understand the MRSA epidemiology because it is, undoubtedly, an important public health concern that requires more attention, in order to achieve an effective response in all sectors.

11.
J Bras Pneumol ; 48(3): e20210283, 2022.
Article in English, Portuguese | MEDLINE | ID: mdl-35830051

ABSTRACT

OBJECTIVES: Non-small cell lung cancer (NSCLC) is an incidental and aggressive type of cancer. Although curative treatment can be offered, the recurrence rate is relatively high. Identifying factors that have a prognostic impact may guide changes in the staging system and recommendations for adjuvant therapy. The aim of this study was to evaluate the impact of microvascular invasion on the 5-year overall survival (OS) of patients with resected NSCLC treated at a reference cancer center. METHODS: This retrospective, observational cohort study included patients diagnosed with early-stage NSCLC (clinical stages I-IIIA), treated with curative-intent surgery at the Brazilian National Cancer Institute between 2010 and 2016. RESULTS: The dataset comprised 91 surgical patients, mostly females and white, with a mean age of 62 years (range between 29-83). Cases were distributed as stages I, II, and III in 55%, 29%, and 16%. Adenocarcinoma was the predominant histological subtype (67%), and microvascular invasion was present in 25% of the patients. The 5-year OS probability was 60% (95% CI, 48.3-68.9). Among all characteristics, advanced stages (p = 0.001) and the presence of microvascular invasion (p< 0.001) were related to a worse 5-year OS. After adjusting for age group and pathological stage, the presence of microvascular invasion was associated with a 4-fold increased risk of death (HR 3.9, 95% CI, 1.9-8.2). CONCLUSION: The presence of microvascular invasion was an independent factor related to worse survival and, therefore, should be routinely assessed in resected specimens.


Subject(s)
Adenocarcinoma , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies
12.
J. bras. pneumol ; 48(3): e20210283, 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1386056

ABSTRACT

ABSTRACT Objectives: Non-small cell lung cancer (NSCLC) is an incidental and aggressive type of cancer. Although curative treatment can be offered, the recurrence rate is relatively high. Identifying factors that have a prognostic impact may guide changes in the staging system and recommendations for adjuvant therapy. The aim of this study was to evaluate the impact of microvascular invasion on the 5-year overall survival (OS) of patients with resected NSCLC treated at a reference cancer center. Methods: This retrospective, observational cohort study included patients diagnosed with early-stage NSCLC (clinical stages I-IIIA), treated with curative-intent surgery at the Brazilian National Cancer Institute between 2010 and 2016. Results: The dataset comprised 91 surgical patients, mostly females and white, with a mean age of 62 years (range between 29-83). Cases were distributed as stages I, II, and III in 55%, 29%, and 16%. Adenocarcinoma was the predominant histological subtype (67%), and microvascular invasion was present in 25% of the patients. The 5-year OS probability was 60% (95% CI, 48.3-68.9). Among all characteristics, advanced stages (p = 0.001) and the presence of microvascular invasion (p< 0.001) were related to a worse 5-year OS. After adjusting for age group and pathological stage, the presence of microvascular invasion was associated with a 4-fold increased risk of death (HR 3.9, 95% CI, 1.9-8.2). Conclusion: The presence of microvascular invasion was an independent factor related to worse survival and, therefore, should be routinely assessed in resected specimens.


RESUMO Objetivos: O câncer de pulmão não pequenas células (CPNPC) é um tipo incidental e agressivo de câncer. Embora o tratamento curativo possa ser oferecido, a taxa de recidiva é relativamente alta. A identificação de fatores que têm impacto prognóstico pode orientar mudanças no TNM e recomendações para terapia adjuvante. O objetivo deste estudo foi avaliar o impacto da invasão microvascular na sobrevida global (SG) em 5 anos de pacientes com CPNPC ressecado tratados em um centro de referência em câncer. Métodos: Este estudo de coorte retrospectivo e observacional incluiu pacientes diagnosticados com CPNPC em estágio inicial (estágios clínicos I-IIIA), tratados com cirurgia com intenção curativa no Instituto Nacional de Câncer entre 2010 e 2016. Resultados: Foram incluídos 91 pacientes tratados com cirurgia, a maioria mulheres e brancos, com média de idade de 62 anos (variação entre 29-83). Os casos foram distribuídos em estágios I, II e IIIA em 55%, 29% e 16%. Adenocarcinoma foi o subtipo histológico predominante (67%), e a invasão microvascular esteve presente em 25% dos pacientes. A probabilidade de SG em 5 anos foi de 60% (IC 95%, 48,3-68,9). Dentre todas as características analisadas, estágios mais avançados (p = 0,001) e a presença de invasão microvascular (p < 0,001) foram relacionados a uma pior SG em 5 anos. Após ajustar para faixa etária e estágio patológico, a presença de invasão microvascular foi associada a um aumento de 4 vezes no risco de morte (RR 3,9, IC 95%, 1,9-8,2). Conclusão: A presença de invasão microvascular foi um fator independente relacionado a uma pior sobrevida e, portanto, deve ser avaliada rotineiramente em espécimes ressecados.

13.
Arch Biochem Biophys ; 697: 108672, 2021 01 15.
Article in English | MEDLINE | ID: mdl-33189653

ABSTRACT

Multiple sclerosis is a neurodegenerative disease causing disability in young adults. Alterations in metabolism and lipid profile have been associated with this disease. Several studies have reported changes in the metabolism of arachidonic acid and the profile of fatty acids, ceramides, phospholipids and lipid peroxidation products. Nevertheless, the understanding of the modulation of circulating lipids at the molecular level in multiple sclerosis remains unclear. In the present study, we sought to assess the existence of a distinctive lipid signature of multiple sclerosis using an untargeted lipidomics approach. It also aimed to assess the differences in lipid profile between disease status (relapse and remission). For this, we used hydrophilic interaction liquid chromatography coupled with mass spectrometry for phospholipidomic profiling of serum samples from patients with multiple sclerosis. Our results demonstrated that multiple sclerosis has a phospholipidomic signature different from that of healthy controls, especially the PE, PC, LPE, ether-linked PE and ether-linked PC species. Plasmalogen PC and PE species, which are natural endogenous antioxidants, as well as PC and PE polyunsaturated fatty acid esterified species showed significantly lower levels in patients with multiple sclerosis and patients in both remission and relapse of multiple sclerosis. Our results show for the first time that the serum phospholipidome of multiple sclerosis is significantly different from that of healthy controls and that few phospholipids, with the lowest p-value, such as PC(34:3), PC(36:6), PE(40:10) and PC(38:1) may be suitable as biomarkers for clinical applications in multiple sclerosis.


Subject(s)
Lipidomics , Multiple Sclerosis/blood , Phospholipids/blood , Adult , Biomarkers/blood , Biomarkers/metabolism , Female , Humans , Male , Middle Aged , Multiple Sclerosis/metabolism , Phospholipids/metabolism
14.
J Neuroimmunol ; 350: 577433, 2020 Nov 05.
Article in English | MEDLINE | ID: mdl-33176239

ABSTRACT

Antigen-presenting cells participate and are implicated in the pathogenesis of multiple sclerosis. In our study we assessed the frequency of plasmacytoid (pDC) and myeloid (mDC) dendritic cells and the classical, intermediate and non-classical monocytes subsets, as well as their phenotypic and functional profile. We evaluated peripheral blood from relapsing-remitting patients treated with IFN-ß in remission and relapse phases and from healthy subjects. In remission, we observed a decrease of mDC/pDC ratio and a return to normal values in relapse. In both phases the frequency of non-classical monocytes decreases. Concerning the phenotypic characterization, an increased HLA-DR expression was observed in remission and a decrease in relapse, revealing alterations in monocytes and dendritic cells homeostasis.

15.
Pharm Res ; 37(10): 191, 2020 Sep 07.
Article in English | MEDLINE | ID: mdl-32895867

ABSTRACT

Infectious diseases are a major global concern being responsible for high morbidity and mortality mainly due to the development and enhancement of multidrug-resistant microorganisms exposing the fragility of medicines and vaccines commonly used to these treatments. Taking into account the scarcity of effective formulation to treat infectious diseases, nanotechnology offers a vast possibility of ground-breaking platforms to design new treatment through smart nanostructures for drug delivery purposes. Among the available nanosystems, mesoporous silica nanoparticles (MSNs) stand out due their multifunctionality, biocompatibility and tunable properties make them emerging and actual nanocarriers for specific and controlled drug release. Considering the high demand for diseases prevention and treatment, this review exploits the MSNs fabrication and their behavior in biological media besides highlighting the most of strategies to explore the wide MSNs functionality as engineered, smart and effective controlled drug release nanovehicles for infectious diseases treatment. Graphical Abstract Schematic representation of multifunctional MSNs-based nanoplatforms for infectious diseases treatment.


Subject(s)
Communicable Diseases/drug therapy , Drug Delivery Systems , Nanoparticles/chemistry , Silicon Dioxide/chemistry , Humans , Pharmacokinetics
16.
J Neuroimmunol ; 339: 577113, 2020 02 15.
Article in English | MEDLINE | ID: mdl-31778850

ABSTRACT

Our work consists of a pilot study to characterize circulating Th/c1, Th/c2, Th/c17, Treg and Tfh-like populations and IL-17 serum levels of relapsing-remitting (RR) MS patients treated with IFN-ß, compared with healthy controls. In remission RRMS patients, we observe increased Th/c17 cells frequency committed to a Th1 profile and increased soluble IL-17 levels. Moreover, a shift toward Th/c2 with reduction of Tc1 cells and decrease in effector/terminal differentiated compartment of Th1 cells were also observed. Despite RRMS patients being an inactive disease phase, IL-17 and Th/c17 cells seemed to contribute to perpetuating chronic inflammation, besides the altered ratio Th1/Th2.


Subject(s)
Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/drug therapy , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/metabolism , Adult , Female , Humans , Immunologic Factors/pharmacology , Interferon-beta/pharmacology , Male , Middle Aged , Pilot Projects , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/metabolism , T-Lymphocytes, Helper-Inducer/drug effects , T-Lymphocytes, Helper-Inducer/metabolism , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/metabolism , Th1 Cells/drug effects , Th1 Cells/metabolism , Th17 Cells/drug effects , Th17 Cells/metabolism , Treatment Outcome
17.
Antioxidants (Basel) ; 8(8)2019 Jul 30.
Article in English | MEDLINE | ID: mdl-31366068

ABSTRACT

(1) Background: Oxidative stress, chronic inflammation, vasoocclusion, and free iron are all features present in sickle cell disease. Paraoxonases (PON) are a family (PON-1, PON-2, PON-3) of antioxidant enzymes with anti-inflammatory action. Here, for the first time, we described PON-1 activities and PON-1, PON-2, PON-3 polymorphisms in patients with sickle cell disease, homozygous for HbSS, compared with healthy controls. (2) Methods: The groups were matched for age and gender. PON-1 activities (arylesterase and paraoxonase) were determined by enzymatic hydrolysis of phenylcetate and paraoxon, respectively. Polymorphisms were determined by Restriction Fragment Length Polymorphism- Polymerase Chain Reaction (RFLP-PCR). (3) Results: Plasma cholesterol and fractions, ApoA1 and ApoB levels were all decreased in sickle cell disease patients, while anti-oxidized low-density lipoprotein (LDL) antibodies and C-reactive protein were increased. Serum arylesterase activity was lower in sickle cell disease patients when compared with healthy controls. In patients, paraoxonase activity was higher in those with PON-1 RR Q192R polymorphism. In these patients, the increase of serum iron and ferritin levels and transferrin saturation were less pronounced than those observed in patients with QQ or QR polymorphism. No differences were observed with PON-1 L55M, and PON-2 and PON-3 polymorphisms. Multivariate regression analysis showed that transferrin and ferritin concentrations correlated with arylesterase and paraoxonase activities. (4) Conclusions: Both transferrin and ferritin were the main predictors of decreased arylesterase and paraoxonase activities in patients with sickle cell disease. LDL oxidation increased, and RR PON-1 Q192R polymorphism is likely to be a protective factor against oxidative damage in these patients.

18.
J Neuroimmunol ; 326: 49-54, 2019 01 15.
Article in English | MEDLINE | ID: mdl-30476705

ABSTRACT

Our aim was to quantify circulating B cell subsets; immature/transitional, naïve, CD27- and CD27+ memory cells and plasmablasts, in relapsing-remitting multiple sclerosis patients treated with IFN-ß. The most relevant findings were a significant increase of plasmablasts and a decrease of immature/transitional B cells, resulting in a decreased ratio between those cells in relapse RRMS, together with an increase of CD27- and CD27+IgM+ memory B cell subsets in both phases of the disease. These alterations point to an active B cell response, particularly in relapse, and the above referred ratio could constitute a good biomarker of relapse in patients that underwent IFN-ß treatment.


Subject(s)
Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Adult , B-Lymphocyte Subsets/drug effects , B-Lymphocyte Subsets/immunology , Female , Humans , Male , Middle Aged , Plasma Cells/drug effects , Plasma Cells/immunology , Precursor Cells, B-Lymphoid/drug effects , Precursor Cells, B-Lymphoid/immunology
19.
Rev. bras. cancerol ; 64(2): 217-225, abr-jun 2018.
Article in English | LILACS | ID: biblio-1026173

ABSTRACT

Introduction: Tobacco smoke is the leading risk factor for the development of lung cancer (LC). However, several countries have recently reported increases in LC in never-smokers. Objective: The study aimed to verify epidemiological and survival characteristics in never-smoker LC patients. Method: The study was based on a historical cohort of never-smokers with LC diagnosed from 2000 to 2009. Overall survival was compared using log-rank test, and Cox regression analysis was used to identify independent prognostic factors. Results: A total of 254 never-smoker LC patients were studied (median age 65.5 years; 66.5% women). The most common histological type was adenocarcinoma (65.7% in women and 60.0% in men), and the majority of the patients had advanced stages (III-IV) (79.6% in women and 92.8% in men). 9.9% of the patients were treated with surgery (13.1% of women and 3.6% of men). The overall survival rates at one, three, and five years were 37.2%, 14.2%, and 9.5%, respectively. Median overall survival was 8.3 months. Women showed better survival than men (9.6 vs. 6.9 months; p=0.023). Non-surgical treatment (p<0.001), performance status 2-4 (p=0.038), and stages III and IV (p<0.001) were associated with worse overall survival. Conclusions: The majority of LC cases in never-smokers were advanced-stage adenocarcinoma, submitted to non-surgical treatment. Women showed better survival than men. Based on the low overall survival, the data emphasize the importance of early diagnosis of LC in never-smoker patients.


Introducción: El tabaquismo es el factor de riesgo predominante para el de cáncer de pulmón (CP). Sin embargo, un aumento reciente de CP en no fumadores es prominente en algunos países. Objetivo: El objetivo de este estudio fue verificar las características epidemiológicas y de sobrevida en no fumadores con CP. Método: Cohorte histórica de no fumadores con CP diagnosticados de 2000-2009. La supervivencia global fue comparada usando análisis de log-rank y la regresión de Cox para identificar factores pronósticos independientes. Resultados: Una muestra totalizando 254 pacientes no fumadores con CP fue estudiada (mediana de edad: 65,5 años, 66,5% de mujeres). El tipo histológico más común correspondió a adenocarcinoma (65,7% en las mujeres y el 60,0% en los hombres) y la mayoría en estadio avanzado (III-IV) (79,6% en las mujeres y el 92,8% en los hombres). Un total de 9,9% de pacientes fueron tratados con cirugía (13,1% en mujeres y 3,6% en hombres). Las tasas de supervivencia global de 1, 3 y 5 años fueron, respectivamente, el 37,2%, el 14,2% y el 9,5%. La supervivencia mediana global correspondió a 8,3 meses. Fue observada una mejor sobrevida en mujeres que em hombres (9,6 frente a 6,9 meses, p=0,023). El tratamiento no quirúrgico (p <0,001), el estado de equilibrio del estado 2-4 (p=0,038) y los estadios III-IV (p <0,001) se encontraron asociados con una peor sobrevida global. Conclusiones: Se encontró una mayor ocurrencia de adenocarcinoma, estadificación avanzada y tratamiento no quirúrgico. Las mujeres mostraron una sobrevida mejor que los hombres. En función de la baja sobrevida global, estos datos refuerzan la importancia del diagnóstico precoz del CP en no fumadores.


Introdução: O tabagismo é o fator de risco predominante para o desenvolvimento do câncer de pulmão (CP). Contudo, um aumento recente de CP em não fumantes é proeminente em alguns países. Objetivo:O objetivo deste estudo foi verificar as características epidemiológicas e de sobrevida em não fumantes com CP. Método: Coorte histórica de não fumantes com CP diagnosticados de 2000 a 2009. A sobrevivência global foi comparada usando o teste Log-rank e a análise de regressão de Cox foi usada para identificar fatores prognósticos independentes. Resultados: Um total de 254 pacientes com LC não fumantes foram estudados (mediana de idade: 65,5 anos, 66,5% de mulheres). O tipo histológico mais comum foi o adenocarcinoma (65,7% nas mulheres e 60,0% nos homens) e a maioria tinha estadiamento avançado (III-IV) (79,6% nas mulheres e 92,8% nos homens). Um total de 9,9% dos pacientes foi tratado com cirurgia (13,1% em mulheres e 3,6% em homens). As taxas de sobrevida global de 1, 3 e 5 anos foram, respectivamente: 37,2%, 14,2% e 9,5%. A sobrevida global mediana foi de 8,3 meses. As mulheres tiveram melhor sobrevida do que os homens (9,6 vs. 6,9 meses, p=0,023). O tratamento não cirúrgico (p<0,001), o performance status 2-4 (p=0,038) e os estádios III-IV (p<0,001) foram associados com uma sobrevida global pior. Conclusão: Encontrou-se uma maior ocorrência de adenocarcinoma, estadiamento avançado e tratamento não cirúrgico. As mulheres tiveram uma sobrevida maior do que os homens. Em razão da baixa sobrevida global, esses dados reforçam a importância do diagnóstico precoce do CP em não fumantes.


Subject(s)
Humans , Male , Female , Tobacco Smoke Pollution , Lung Neoplasms/epidemiology , Prognosis , Survivorship , Non-Smokers , Lung Neoplasms/diagnosis
20.
J Neuroimmunol ; 318: 65-71, 2018 05 15.
Article in English | MEDLINE | ID: mdl-29506867

ABSTRACT

We characterized circulating gamma-delta T cells in relapsing-remitting multiple sclerosis (RRMS) patients, during remission and relapse phases. In relapse, we observed a decrease of circulating CCR5+ γδ TEMRA cell subset, together with a decrease in EOMES and granzyme B mRNA expression in γδ T cells, suggesting a reduction of the cytotoxic potential of this subset. Moreover, we also found a higher frequency of IFNγ+ γδ T cells, which may indicate that these cells are assuming a more regulatory function associated to a Th1 profile. These results suggest a specific release from the periphery of a particular γδ T cell subset, expressing CCR5 and belonging to an effector compartment, supporting the idea that γδ T cells could play a role in MS relapse.


Subject(s)
Intraepithelial Lymphocytes/immunology , Multiple Sclerosis, Relapsing-Remitting/immunology , T-Lymphocyte Subsets/immunology , Adult , Female , Humans , Male , Middle Aged , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...